internalmed | Unsorted

Telegram-канал internalmed - Internal Medicine

4554

Stay up-to-date on topics of Internal Medicine including educational cases, guidelines, important research findings. Introduce this channel to your friends interested in Internal Medicine. Contact admin: @aasohrab

Subscribe to a channel

Internal Medicine

💢 Health Benefits of Creatine Supplements


https://www.sciencedaily.com/releases/2025/06/250610004101.htm

🆔 @InternalMed
.

Читать полностью…

Internal Medicine

📣 کنفرانس علمی ماهانه (حضوری-آنلاین)

✳️ موضوع: Update #HBV & #HCV and its management

🏢 محل برگزاری: خیابان کارگر شمالی، بالاتر از جلال آل احمد، خیابان هفتم، بن بست اول، پلاک 37

👈 پنجشنبه 26 تیرماه 1404 ساعت 10:00 صبح

📌 شناسه برنامه: 238036

👈 مشاهده کنفرانس بصورت Live از طریق https://iagh.org/live/ امکان پذیر است.

..................................

🌹🌹/channel/IAGH94

❇️❇️https://www.instagram.com/iagh97/

🌍info@iagh.org

https://wa.me/+989396807473

Читать полностью…

Internal Medicine

💢 My adult patient’s hypercholesterolemia is not responding to statins—what’s next?

A 65-year-old man with a history of hypercholesterolemia and hypertension well controlled on losartan 25 mg daily presents for follow-up on his cholesterol. He has no history of smoking, alcohol use, or heart disease. In addition to losartan, he has been taking rosuvastatin 40 mg daily for the past 2 months. Despite these measures, he has been unable to achieve his goal low-density lipoprotein cholesterol (LDL-C) level of less than 100 mg/dL. His lipid panel is LDL-C 165 mg/dL, high-density lipoprotein 45 mg/dL, and total cholesterol 210 mg/dL. Before starting statin therapy, his lipid panel was LDL-C 185 mg/dL, high-density lipoprotein 45 mg/dL, and total cholesterol 230 mg/dL. His current 10-year risk of atherosclerotic cardiovascular disease (ASCVD) is 14.6%. What are the next steps in managing this patient’s hypercholesterolemia?



🆔 @internalmed
.

Читать полностью…

Internal Medicine

A new study in the journal Nature Medicine has given us the most comprehensive look yet at all the different ways in which GLP-1 drugs might be beneficial beyond their original intention of treating diabetes.

In this study, researchers used a “discovery” approach to look for any associations they could find between GLP-1 receptor agonist drugs and 175 health outcomes.

The analysis used data on over 2 million diabetic people from the US Veterans Study. The study compared people taking GLP-1s to people prescribed a different diabetes drug.

Overall, using a GLP-1 compared to another diabetes drug was associated with a whole slew of beneficial outcomes.

All of the conditions in blue below indicate significant reductions in risk for those taking GLP-1 drugs compared to usual care.

📎 Link


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Iron Deficiency in Adults - JAMA Review


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Five Things to Know About Pleural Infection


🆔 @internalmed
.

Читать полностью…

Internal Medicine

Diabetic ketoacidosis induced by a SGLT2-inhibitor


🆔 @internalmed
.


در این باره توجه شما را به پست های زیر هم جلب می کنم:

👉 /channel/internalmed/13584

👉 /channel/internalmed/12642

👉 /channel/internalmed/11875


🆔 @internalmed
.

Читать полностью…

Internal Medicine

🎧 Chronic Kidney Disease: What Generalists Need to Know

https://podcasts.apple.com/us/podcast/annals-on-call-podcast/id1424411912?i=1000706438820


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Tirzepatide Tops Semaglutide for Weight Loss


In the first head-to-head
trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss, and reduction in waist circumference, than semaglutide (Ozempic for type 2 diabetes and Wegovy for weight loss; Novo Nordisk) in adults with obesity but without type 2 diabetes over 72 weeks in the SURMOUNT-5 trial.


🆔 @internalmed
.

Читать полностью…

Internal Medicine

🎧 A 45-Year-Old Snorer

https://podcasts.apple.com/us/podcast/harrisons-podclass-internal-medicine-cases-and-board-prep/id1453765092?i=1000706861234


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Central Nervous System Tuberculomas


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Abdominal Aortic Occlusion from Left Atrial Myxoma Embolism


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Updates to Management of Adults With Chronic Kidney Disease


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Biden Wanted Medicaid to Pay for Weight-Loss Drugs. Trump Just Said it Doesn’t Have to


https://www.hepmag.com/article/biden-wanted-medicaid-pay-weightloss-drugs-trump-just-said


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Ménétrier's Disease


🆔 @Internalmed
.

Читать полностью…

Internal Medicine

🔥


💢 Time to rethink microscopic colitis?

New study finds NO causative association between NSAIDs, PPIs, statins, or ACE inhibitors with microscopic colitis.

📎 Link


🆔 @GIJournalClub
.

Читать полностью…

Internal Medicine

💢 Amoxicillin rash in infectious mononucleosis


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 39-Year-Old Man With Reflux, Diarrhea, and Abdominal Pain


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial

In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes.

Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity.

📎 Link


🆔 @GIJournalClub
.

Читать полностью…

Internal Medicine

💢 Colonic Angiodysplasia


🆔 @internalmed
.

Читать полностью…

Internal Medicine

فیلم/لیورگل در درمان کبد چرب موثر نیست

🔹فانا: علیرضا استقامتی استاد غدد درون‌ریز و متابولیسم (بالغین) دانشگاه علوم پزشکی تهران در گفت‌وگو با فانا توضیح داد: بیماری کبد چرب هم در جامعه و هم در افراد دیابتی شایع است. حدود نیمی از افراد جامعه ممکن است کبد چرب داشته باشند. همچنین تا حدود دو سوم از افراد مبتلا به دیابت ممکن است دچار کبد چرب شوند. بیماری کبد چرب فقط تجمع چربی در کبد نیست. این بیماری باعث التهاب در کبد می‌شود و اگر کنترل نشود منجر به فیبروز، نارسایی کبدی یا سیروز و بدخیمی می‌شود. افراد مبتلا به کبد چرب مستعد ابتلا به بیماری‌های قلبی عروقی مانند سکته‌های قلبی و مغزی، نارسایی قلبی و ... هستند. تنها درمان فعلی کبد چرب، رژیم غذایی سالم و ورزش منظم است. داروهای جدید درمان چاقی ممکن است روی التهابات کبد و فیروز هم اثر بگذارند و اگر مطالعات آنها کامل شود شاید در آینده بتوانیم از آنها هم استفاده کنیم. عرقیات و لیورگل هیچیک از نظر علمی، شواهد مستند و علمی برای درمان کبد چرب ندارند. قهوه هم در مطالعات مشاهده‌ای تا حدی در درمان کبد چرب موثر بوده است
@phanair

Читать полностью…

Internal Medicine

💢 The ’Silk Road’ that Leads to Infliximab: A Severe Case of Behcet’s Disease


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Lifestyle Modifications in MASLD Management


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Adrenal insufficiency: identification and management—summary of new NICE guidance


🆔 @internalmed
.

Читать полностью…

Internal Medicine

🎧 Temporal Arteritis

https://podcasts.apple.com/us/podcast/gpnotebook-podcast/id1478649728?i=1000706787480


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Taking A Clinical History in Iron Deficiency Anemia


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Pigmented Lesion on the Hard Palate


🆔 @internalmed
.

Читать полностью…

Internal Medicine

🎧 A 35-year-old with Burning Abdominal Pain

https://podcasts.apple.com/us/podcast/harrisons-podclass-internal-medicine-cases-and-board-prep/id1453765092?i=1000705713245


🆔 @internalmed
.

Читать полностью…

Internal Medicine

💢 Gout 2025


🆔 @internalmed
.

Читать полностью…

Internal Medicine

سلام
اطلاعاتی در مورد بیماری سرخک برای کادر سلامت.
امیدوارم که مورد استفاده قرار گیرد.
خوش حال می‌شوم که پاسخ گوی پرسش ها باشم.🙏🏻

Читать полностью…
Subscribe to a channel